Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).
Kelaidi C, Ades L, Chevret S, Sanz M, Guerci A, Thomas X, de Botton S, Raffoux E, Rayon C, Fegueux N, Bordessoule D, Rigal-Huguet F, Link H, Stoppa A, Vekhoff A, Meyer-Monard S, Castaigne S, Dombret H, Degos L, Fenaux P. Kelaidi C, et al. Among authors: vekhoff a. Leukemia. 2006 May;20(5):905-7. doi: 10.1038/sj.leu.2404158. Leukemia. 2006. PMID: 16541143 Clinical Trial. No abstract available.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).
Thomas X, Fenaux P, Dombret H, Delair S, Dreyfus F, Tilly H, Vekhoff A, Cony-Makhoul P, Leblond V, Troussard X, Cordonnier C, de Revel T, Simon M, Nicolini F, Stoppa AM, Janvier M, Bordessoule D, Rousselot P, Ffrench M, Marie JP, Archimbaud E. Thomas X, et al. Among authors: vekhoff a. Leukemia. 1999 Aug;13(8):1214-20. doi: 10.1038/sj.leu.2401474. Leukemia. 1999. PMID: 10450749 Clinical Trial.
Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.
Thomas X, Dombret H, Cordonnier C, Pigneux A, Gardin C, Guerci A, Vekhoff A, Sadoun A, Stamatoullas A, Fegueux N, Maloisel F, Cahn JY, Reman O, Gratecos N, Berthou C, Huguet F, Kotoucek P, Travade P, Buzyn A, de Revel T, Vilque JP, Naccache P, Chomienne C, Degos L, Fenaux P. Thomas X, et al. Among authors: vekhoff a. Leukemia. 2000 Jun;14(6):1006-13. doi: 10.1038/sj.leu.2401800. Leukemia. 2000. PMID: 10865965
All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
Belhabri A, Thomas X, Wattel E, Chelghoum Y, Anglaret B, Vekhoff A, Reman O, Dombret H, Dhedin N, Michallet M, Fière D, Archimbaud E. Belhabri A, et al. Among authors: vekhoff a. Hematol J. 2002;3(1):49-55. doi: 10.1038/sj.thj.6200141. Hematol J. 2002. PMID: 11960396 Clinical Trial.
Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial.
de Botton S, Chevret S, Coiteux V, Dombret H, Sanz M, San Miguel J, Caillot D, Vekhoff A, Gardembas M, Stamatoulas A, Conde E, Guerci A, Gardin C, Fey M, Cony Makhoul D, Reman O, de la Serna J, Lefrere F, Chomienne C, Degos L, Fenaux P; European APL group. de Botton S, et al. Among authors: vekhoff a. Leukemia. 2003 Feb;17(2):339-42. doi: 10.1038/sj.leu.2402807. Leukemia. 2003. PMID: 12592333 Clinical Trial.
Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
Callens C, Chevret S, Cayuela JM, Cassinat B, Raffoux E, de Botton S, Thomas X, Guerci A, Fegueux N, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Ferrand A, Sanz M, Chomienne C, Fenaux P, Dombret H; European APL Group. Callens C, et al. Among authors: vekhoff a. Leukemia. 2005 Jul;19(7):1153-60. doi: 10.1038/sj.leu.2403790. Leukemia. 2005. PMID: 15889156
Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy.
Thomas X, Le Q, Botton Sd, Raffoux E, Chelghoum Y, Pautas C, Dreyfus F, Dhedin N, Vekhoff A, Troncy J, Pigneux A, Revel Td, Reman O, Travade P, Thiebaut A, Guerci A, Elhamri M, Fenaux P, Dombret H, Michallet M. Thomas X, et al. Among authors: vekhoff a. Leuk Lymphoma. 2005 Jul;46(7):1007-16. doi: 10.1080/10428190500084837. Leuk Lymphoma. 2005. PMID: 16019551
A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.
Lévy V, Zohar S, Bardin C, Vekhoff A, Chaoui D, Rio B, Legrand O, Sentenac S, Rousselot P, Raffoux E, Chast F, Chevret S, Marie JP. Lévy V, et al. Among authors: vekhoff a. Br J Cancer. 2006 Aug 7;95(3):253-9. doi: 10.1038/sj.bjc.6603265. Epub 2006 Jul 18. Br J Cancer. 2006. PMID: 16847470 Free PMC article. Clinical Trial.
75 results